Ana sayfa | MS’in Derinliği  | MS Slide Resource

References

1. Schapiro RT, Langer SL. Symptomatic therapy of multiple sclerosis. Curr Opin Neurol 1994;7(3):229-233.

2. Schapiro RT. Symptom management in multiple sclerosis. Ann Neurol 1994;36(suppl):S123-S129.

3. Shefner JM, Mackin GA, Dawson DM. Lower motor neuron dysfunction in patients with MS. Muscle and Nerve 1992:15:1265-1270.

4. Ramirez-Lassepas M, Tulloch JW, Quinones MR, Snyder BD. Acute radicular pain as a presenting symptom in MS. Arch Neurol 1992;42:255-258.

5. Coleman RJ, Quinn NP, Marsden CD. Multiple sclerosis presenting as adult onset dystonia. Mov Disorders 1988;3:329-332.

6. Barnes D, McDonald WI. The ocular manifestations of MS. 2. Abnormalities of eye movements. J Neurol Neurosurg Psychiat 1992;55:863-868.

7. Sullivan F, Hutchinson M, Bahandekas S, Moore RE. Chronic hypothermia in MS. J Neurol Neurosurg Psychiat 1987;50:813-815.

8. Daugherty WT, Lederman RJ, Nodar RH, Conomy JP. Hearing loss in MS. Arch Neurol 1983;40:33-35.

9. Matthews WB. Demyelinating disease. In: Weatherall DJ, Ledingham JCG, Warell DA. (eds). Oxford Textbook of Medicine. Oxford:Oxford University Press, 1988;2:21.211-21.218.

10. Bauer HJ. Problems of symptomatic therapy in MS. Neurology 1978;28(2):8-20.

11. Matthews WB. Clinical aspects. In: Matthews WB (ed). McAlpine's Multiple Sclerosis. 2nd ed. Edinburgh:Churchill Livingstone, 1991:43-298.

12. Silberberg DH. Section eleven / The demyelinating diseases. In: Wyngaarden JB, Smith LH (eds). Cecil Textbook of Medicine. Philadelphia:WB Saunders Company, 1988:2211-2217.

13. McDonald E. Multiple sclerosis: common management issues. Aust Fam Physician 1992;21(10):1421-1424.

14. Mitchell G. Update on multiple sclerosis therapy. Med Clin North Am 1993;77(1):231-249.

15. Noseworthy JH. Therapeutics of multiple sclerosis. Clin Neuropharmacol 1991;14(1):49-61.

16. Weinshenker BG, Penman M, Bass B, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992;42:1468-1471.

17. Osterman PO, Westerberg CE. Paroxysmal attacks in multiple sclerosis. Brain 1975;98:189-202.

18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey (in press).

19. Thompson AJ, McDonald WI. Multiple sclerosis and its pathophysiology. In: Ashbury AK, McKhann GM, McDonald WI (eds). Diseases of the Nervous System. Philadelphia:WB Saunders Company, 1992:1209-1228.

20. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: A geographically based study. 1. Clinical course and disability. Brain 1989;112:133-146.

21. Fowler TJ. Demyelinating disease of the central nervous system. In Marsden CD, Fowler TJ (eds). Clinical Neurology. London:Edward Arnold, 1989:344-352.

22. Francis DA. The current therapy of multiple sclerosis. J Clin Pharm Ther 1993;18:77-84.

23. Management of psychological symptoms in multiple sclerosis. In: Clanet M (Chairman). The symptoms of multiple sclerosis and their management. Proceedings of The MS Forum Modern Management Workshop, Paris, April 1994:2-7.

24. Barnes D, Hughes RAC, Wade-Jones OM, et al. Trial of versus IV methylprednisolone in acute relapses of MS. J Neurol 1995;6:S23.

25. Kurtzke JF, Beebe GW, Nagler B, et al. Studies on the natural history of multiple sclerosis. 8. Early prognostic features of the later course of the illness. J Chronic Diseases 1977;50:523-531.

26. Goodkin DE. The natural history of multiple sclerosis. In: Rudick RA, Goodkin DE (eds). Treatment of Multiple Sclerosis: Trial Design, Results, and Future Perspectives. London:Springer-Verlag, 1992:17-45.

27. Weinshenker BG, Ebers GC. The natural history of multiple sclerosis. Can J Neurol Sci 1987;14:255-261.

28. Kelly R. Clinical aspects of MS. In: Koetsier JC (ed). Handbook of Clinical Neurology Vol. 3(47): Demyelinating diseases. Elsevier Science Publishers B.V. 1985:49-78.

29. Troiano R, Cook ST, Dowling PC. Steroid therapy in multiple sclerosis. Point of view. Arch Neurol 1987;44:803-807.

30. Sibley WA, the Therapeutic Claims Committee of the International Federation of Multiple Sclerosis Societies. Therapeutic claims in multiple sclerosis. 3rd edition. New York:Demos Publications, 1992:29-42.

31. Myers LW. Treatment of multiple sclerosis with ACTH and corticosteroids. In: Rudick RA, Goodkin DE (eds). Treatment of Multiple Sclerosis: Trial Design, Results, and Future Perspectives. London:Springer-Verlag, 1992:135-156.

32. Kupersmith MJ, Kaufman D, Paty DW, et al. Megadose corticosteroids in multiple sclerosis. Neurology 1994;44:1-4.

33. Milligan NM, Newcombe R, Compston DAS. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. clinical effects. J Neurol Neurosurg Psychiat 1987;50:511-516.

34. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993;329(24):1764-1769.

35. Beck RW, Cleary PA, Anderson MM, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326(9):581-588.

36. Alam SM, Kyriakides T, Lawden M, et al. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol, Neurosurg Psychiatr 1993;56:1219-1220.

37. Beck RW, and The Optic Neuritis Study Group. Corticosteroid treatment of optic neuritis: a need to change treatment practices. Neurology 1992;42:1133-1135.

38. British Society of Rehabilitation Medicine. Working party report on multiple sclerosis. April 1993.

39. Kraft GH, Freal JE, Coryell JK. Disability, disease duration, and rehabilitation service needs in multiple sclerosis: patient perspectives. Arch Phys Med Rehabil 1986;67(3):164-168.

40. Scheinberg L, Holland NJ, Kirschenbaum M, et al. Comprehensive long-term care of patients with multiple sclerosis. Neurology 1981;31:1121-1123.

41. Management of spasticity in multiple sclerosis. In: Clanet M (Chairman). The symptoms of multiple sclerosis and their management. Proceedings of The MS Forum Modern Management Workshop, Paris, April 1994:21-25.

42. Calne DB. The pharmacology of spasticity. In Klawans HL (ed). Clinical Neuropharmacology, Vol. 1. New York:Raven Press, 1976:137-145.

43. Noth J. Trends in the pathophysiology and pharmacotherapy of spasticity. J Neurol 1991;238:131-139.

44. Waldman HJ. Centrally acting skeletal muscle relaxants and associated drugs. J Pain and Symptom management 1994;9(7):434-441.

45. Young RR. Spasticity: a review. Neurology 1994;44(suppl 9):S12-S20.

46. Nguyen JP, Degos JD. Thalamic stimulation and proximal tremor: a specific target in the nucleus ventrointermedius thalami. Arch Neurol 1993;50:498-500.

47. Hewer RL, Cooper R, Morgan MH. An investigation into the value of treating intention tremor by weighting the affected limb. Brain 1972;95:579-590.

48. Sechi GP, Zuddas M, Piredda M, et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long term follow-up. Neurology 1989;39:1113-1115.

49. Management of tremor in multiple sclerosis. In: Clanet M (Chairman). The symptoms of multiple sclerosis and their management. Proceedings of The MS Forum Modern Management Workshop, Paris, April 1994:26-29.

50. Hallett M, Lindsey JW, Adelstein BD, et al. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology 1985;35:1374-1377.

51. Aisen ML, Arnold A, Baiges I, et al. The effect of mechanical damping loads on disabling action tremor. Neurology 1993;43:1346-1350.

52. Speelman JD, van Manen J. Stereotactic thalotomy for the relief of intention tremor of multiple sclerosis. J Neurol Neurosurg Psychiat 1984;47:596-599.

53. Management of bladder and bowel dysfunction in multiple sclerosis. In: Clanet M (Chairman). The symptoms of multiple sclerosis and their management. Proceedings of The MS Forum Modern Management Workshop, Paris, April 1994:13-17.

54. Fowler CJ, van Kerrebroeck P, Nordenbo A, et al. Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. J Neurol Neurosurg Psychiat 1992;55:986-989.

55. Fowler CJ. Bladder dysfunction in multiple sclerosis: causes and treatment. The International MS Journal; 1994;1(3):99-107.

56. van Poppel H, Vereecken RL, Leruitte A. Neuro-muscular dysfunction of the lower urinary tract in multiple sclerosis. Paraplegia 1983;21:374-379.

57. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis: a population survey. Gastroenterology 1990;98:1538-1542.

58. Chia Y-W, Fowler CJ, Kamm MA, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 1995;242:105-108.

59. Betts CD, Jones SJ, Fowler CG, et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. Brain 1994;117:1303-1310.

60. Lundberg PO. Sexual dysfunction in female patients with multiple sclerosis. Int Rehab Med 1981;3(1):32-34.

61. Management of sexual dysfunction in multiple sclerosis. In: Clanet M (Chairman). The symptoms of multiple sclerosis and their management. Proceedings of The MS Forum Modern Management Workshop, Paris, April 1994:18-20.

62. Minderhoud JM, Leemhuos JG, Kremer J, et al. Sexual disturbances arising from multiple sclerosis. Acta Neurol Scand 1984;70:299-306.

63. Rudick RA. Helping patients live with multiple sclerosis. What primary care physicians can do. Postgrad Med 1990;88(2):197-207.

64. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol 1990;47:98-104.

65. Sadovnick AD, Eisen RN, Ebers GC, et al. Causes of death in patients attending multiple sclerosis clinics. Neurology 1993;41:1193-1196.

66. Schiffer RB. The spectrum of depression in multiple sclerosis: an approach for clinical management. Arch Neurol 1987;44:596-599.

67. Larcombe NA, Wilson PH. An evaluation of cognitive-behaviour therapy for depression in patients with multiple sclerosis. Br J Psychiatry 1984;145:366-371.

68. Crawford JD, McIvor GP. Group psychotherapy: benefits in multiple sclerosis. Arch Phys Med Rehabil 1985;66:810-813.

69. Rao SM, Reingold SC, Ron MA, et al. Workshop on neurobehavioural disorders in multiple sclerosis. Arch Neurol 1993;50:658-662.

70. Prosiegel M, Michael C. Neuropsychology and multiple sclerosis: diagnostic and rehabilitative approaches. J Neurological Sci 1993;155(suppl):S51-S54.

71. The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987;14:273-278.

72. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.

73. Fisk JD, Pontefract A, Ritvo PG, et al. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci 1994;21:9-14.

74. Bertolone K, Coyle PK, Krupp LB, et al. Cytokine correlates of fatigue in multiple sclerosis. Neurology 1993;43:A356.

75. Sandroni P, Walker C, Starr A. Fatigue in patients with multiple sclerosis: motor pathway conduction and event-related potentials. Arch Neurol 1992;49:517-524.

76. Espir MLE, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiat 1970;33:528-531.

77. Management of fatigue in multiple sclerosis. In: Clanet M (Chairman). The symptoms of multiple sclerosis and their management. Proceedings of The MS Forum Modern Management Workshop, Paris, April 1994:8-12.

78. Berger JR, Sheremata WA, Melamed E. Paroxysmal dystonia as the initial manifestation of multiple sclerosis. Arch Neurol 1984;41:747-750.

79. Matthews WB. Paroxysmal symptoms in multiple sclerosis. J Neurol Neurosurg Psychiat 1975;38:617-623.

80. Maimone D, Reder AT, Finocchiaro F, et al. Internal capsule plaque and tonic spasms in multiple sclerosis. Arch Neurol 1991;48:427-429.

81. Management of paroxysmal symptoms in multiple sclerosis. In: Clanet M (Chairman). The symptoms of multiple sclerosis and their management. Proceedings of The MS Forum Modern Management Workshop, Paris, April 1994:30-33.

82. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology 1988;38:1830-1834.

83. Stenager E, Knudsen L, Jensen K, et al. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991;84:197-200.

84. Rushton JG, Olafson RA. Trigeminal neuralgia associated with multiple sclerosis: report of 35 cases. Arch Neurol 1965;13:383-386.

85. Management of pain in multiple sclerosis. In: Clanet M (Chairman). The symptoms of multiple sclerosis and their management. Proceedings of The MS Forum Modern Management Workshop, Paris, April 1994:34-37.

86. Moulin DE. Pain in multiple sclerosis. Neurologic Clinics 1989;7:321-331.

87. Rolak LA, Brown S. Headaches and MS - a clinical study and review of the literature. J Neurol 1990;237:300-302.

88. DeLisa JA, Hammond MC, Mikulic MA, Miller RM. Multiple sclerosis: part 1. Common physical disabilities and rehabilitation. Am Fam Physician 1985;32(4):157-163.

Bu sayfadaki bilginin en son güncellendiği/doğrulandığı tarih:

11/09/2001

Ana sayfa | Bağlantılar | Kayıt ve geri bildirim | Sözlükçe | Arama motoru ve site haritası | Yerel Bilgiler | Yardım| Bir arkadaşa söyleyin | Sorumluluk almama | Basın Bilgileri | Schering